Skip to content

Released Nov 12, 2026, after the close

10-Q filed Nov 12, 2026, 43 days after period end · 0001493152-26-051384

Q2 2027 · 10-Q
Revenue$40.08M+10.4% vs Q2 2026+23.9% vs Q1 2027
Net Income$17.32M+26.4% vs Q2 2026+193.0% vs Q1 2027
EPS Diluted$0.01±0.0% vs Q2 2026±0.0% vs Q1 2027
Gross Profit$15,987,295+13.6%
Operating Income$9,925,451+20.8%
Operating Cash Flowderived-$3,074,612N/M
Free Cash Flowderived-$3,806,796N/M
Margins · derived
Gross margin39.9%+1.1 pt vs Q2 2026
Operating margin24.8%+2.1 pt vs Q2 2026
Net margin43.2%+5.5 pt vs Q2 2026

What the release said

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and

Elite Pharmaceuticals reported consolidated revenues of $40.1 million for the three months ended September 30, 2026, an increase of $3.8 million or approximately 10.4% over the prior-year period.2

Income from operations was $9.9 million, an increase of $1.7 million or approximately 21% compared with the same period of the prior fiscal year.2

Management will host a conference call on November 13, 2026 at 11:30 AM EST to discuss the Second Quarter results and recent business developments.3456

Consolidated revenues, three months ended September 30, 2026
$40.1 million Increase of $3.8 million or approximately 10.4% compared with the same period of the prior fiscal year.2
Income from operations, second quarter fiscal 2027
$9.9 million Increase of $1.7 million or approximately 21% compared with the same period of the prior fiscal year.2
Net income attributable to common shareholders, Second Quarter
$17.3 million2
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ2 2027Q2 2026Q2 2025Q2 2024
Revenue$40.08M$36.32M$18.88M$14.16M
Net Income$17.32M$13.70M-$11.04M$14.93M
EPS Diluted$0.01$0.01-$0.01$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR